Cohere targets up to CAD 7bln series E at a CAD 35.7bln valuation
Newsquawk Staff ·
Cohere targets up to CAD 7bln series E at a CAD 35.7bln valuation.
What it means
Large late-stage private rounds in the AI space have followed a recognisable pattern: each successive raise marks a step-change in valuation rather than incremental progression, with the round size and price set less by fundamentals than by strategic positioning among foundation-model developers competing for capital and compute. The figures here are targets, not a closed round, and the distinction matters: announced targets in private markets frequently land below the initial ask or arrive restructured with preferred terms, ratchets, or strategic investor participation that changes the effective price. The relevant precedent is that Canadian and US frontier-model developers of this tier have tended to anchor rounds around a strategic backer, often a cloud or chip counterparty whose investment doubles as a commercial compute arrangement, so the composition of the book matters more than the headline number. Worth watching are confirmation of the close, the identity of lead investors, and any revenue or annualised run-rate disclosures attached to the pricing, since private marks in this sector have historically diverged sharply from implied revenue multiples in public peers. There is no direct listed proxy, so any read-through runs through the listed strategic investors and the broader AI capex complex rather than the issuer itself.
Sources
- Meta (META) reaches a settlement with a second teen during the Los Angeles trial over social media harms
- Hunterbrook says new trade data suggests Bloom Energy (BE) has reopened a route for scandium-containing components from China to the US, despite the company repeatedly denying it relies on Chinese scandium for its fuel cells
- CFTC will sue Utah to halt the state’s lawsuit against Kalshi, arguing federal law grants it exclusive authority, CNBC reports
- General Dynamics (GD) discloses receipt of a subpoena from the US DoD Inspector General, according to its 10-Q filing
- AbbVie (ABBV) says they expect to pursue bolt-on deals rather than large transformational M&A
Related headlines
- Deere (DE) to re-hire around 400 workers2 hours ago
- US EQUITY OPEN: Tech tumbles amid AI fears following disappointing earnings2 hours ago
- Chevron (CVX) CEO Wirth says he is optimistic the company will successfully conclude Iraq negotiations and establish operations as early as next year, according to a CNBC interview 2 hours ago
- CNBC's Faber is hearing Lumentum (LITE) deal is on track for potential announcement next week2 hours ago
- Newsquawk US Daily Equity Opening News - INTC plunges on weak outlook, cash flows; AMZN report underwhelms3 hours ago
- [EARNINGS ANALYSIS] Tech continues to get slammed as AI fears mount on dismal reports3 hours ago
- AbbVie Inc. (ABBV) Q3 2026 (USD): Adj. EPS 3.82 (exp. 3.73), Revenue 17.4bln (exp. 17.3bln)4 hours ago
- Dominion Energy Inc (D) Q3 2026 (USD): Operating EPS 1.28 (exp. 1.21), Revenue 5.62bln (exp. 4.89bln); Current FY EPS 3.45-3.69 (exp. 3.59)4 hours ago
- UK CMA opens investigation into Meta (META) to examine concerns that its terms and conditions unfairly harm news publishers and other content businesses5 hours ago
- General Dynamics Corporation (GD) Q3 2026 (USD): EPS 4.49 (exp. 4.12), Revenue 14.6bln (exp. 13.7bln)5 hours ago
- Colgate-Palmolive Company (CL) Q3 2026 (USD): Adj. EPS 0.97 (exp. 0.93), Sales 5.37bln (exp. 5.34bln)5 hours ago
- Kenvue Inc. (KVUE) Q3 2026 (USD): Adj. EPS 0.29 (exp. 0.29), Revenue 3.9bln (exp. 3.86bln)5 hours ago
- Regeneron Pharmaceuticals Inc. (REGN) Q3 2026 (USD) Adj. EPS 20.07 (exp. 16.19), Revenue 5.1bln (exp. 4.56bln); Sees FY outlook for capex of USD 1.05 - 1.1bln5 hours ago
- ExxonMobil Holdings (XOM) Q3 2026 (USD): adj. EPS 4.23 (exp. 4.11), Revenue (exp. 105.49bln), adj. Net 17.5bln (exp. 16.6bln). 2027 buyback of USD 20bln.5 hours ago
- Chevron (CVX) expects Q4 capital expenditure to increase, although full-year capex is expected to remain at the low end of its annual guidance range5 hours ago